Enveric Biosciences, Inc. (NASDAQ:ENVB) Stock Short Interest Report for October

Enveric Biosciences, Inc. (NASDAQ:ENVB) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 38,702 shares, an increase of 150.7% from the September 30th total of 15,435 shares. Currently, 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 73,479 shares, the short-interest ratio is currently 0.5 days.

Enveric Biosciences Stock Down 0.3%

Shares of Enveric Biosciences stock traded down $0.01 during mid-day trading on Friday, hitting $1.46. The stock had a trading volume of 5,027 shares, compared to its average volume of 1,306,802. The firm has a 50-day moving average of $1.45 and a two-hundred day moving average of $2.03. The firm has a market cap of $6.52 million, a P/E ratio of -0.12 and a beta of 1.18. Enveric Biosciences has a 12-month low of $1.17 and a 12-month high of $13.25.

Enveric Biosciences (NASDAQ:ENVB) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.76) earnings per share for the quarter.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Wall Street Zen raised shares of Enveric Biosciences from a “sell” rating to a “hold” rating in a report on Sunday, August 23rd. Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock currently has an average rating of “Sell”.

About Enveric Biosciences

Enveric Biosciences, Inc is a biotechnology company focused on discovering and developing novel small-molecule therapeutics for cancer and central nervous system disorders. The company’s research uses insights from cannabinoid science and psychedelic-inspired compounds to identify potential treatments for conditions with significant unmet medical needs.

Enveric has developed a portfolio of proprietary drug candidates and intellectual property, including programs aimed at mental health conditions such as depression and other neurological disorders, as well as therapies intended to address cancer-related symptoms and supportive-care needs.